| References |
Please submit your publication
Barker E, Morgan A, Barclay JW. A Caenorhabditis elegans model of autosomal dominant adult-onset neuronal ceroid lipofuscinosis identifies ethosuximide as a potential therapeutic. Hum Mol Genet 2023 32(11) 1772-1785
[ PubMed ID = 36282524 ]
[ RRC reference ]
|
Mulcahy B, Ibbett P, Holden-Dye L, O'Connor V. The Caenorhabditis elegans cysteine-string protein homologue DNJ-14 is dispensable for neuromuscular junction maintenance across ageing. J Exp Biol 2019 222(Pt 22)
[ PubMed ID = 31624097 ]
[ RRC reference ]
|
Chen X, McCue HV, Wong SQ, Kashyap SS, Kraemer BC, Barclay JW, Burgoyne RD, Morgan A. Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener 2015 10 51
[ PubMed ID = 26419537 ]
[ RRC reference ]
|
McCue HV, Chen X, Barclay JW, Morgan A, Burgoyne RD. Expression profile of a Caenorhabditis elegans model of adult neuronal ceroid lipofuscinosis reveals down regulation of ubiquitin E3 ligase components. Sci Rep 2015 5 14392
[ PubMed ID = 26395859 ]
[ RRC reference ]
|
Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, Graham ME, Jenn RC, Barclay JW, Burgoyne RD, Morgan A. Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. Hum Mol Genet 2014 23(22) 5916-27
[ PubMed ID = 24947438 ]
[ RRC reference ]
|
|